Nicholas Hoffman & Company LLC. raised its position in Pfizer Inc. (NYSE:PFE – Free Report) by 6.6% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 44,230 shares of the biopharmaceutical company’s stock after acquiring an additional 2,730 shares during the quarter. Nicholas Hoffman & Company LLC.’s holdings in Pfizer were worth $1,238,000 at the end of the most recent quarter.
Several other large investors also recently bought and sold shares of the company. Cantor Fitzgerald Investment Advisors L.P. acquired a new stake in shares of Pfizer during the fourth quarter worth approximately $16,166,000. First Heartland Consultants Inc. grew its position in shares of Pfizer by 43.3% during the fourth quarter. First Heartland Consultants Inc. now owns 13,013 shares of the biopharmaceutical company’s stock worth $375,000 after buying an additional 3,933 shares in the last quarter. ORG Partners LLC grew its position in shares of Pfizer by 1,729.9% during the second quarter. ORG Partners LLC now owns 47,028 shares of the biopharmaceutical company’s stock worth $1,327,000 after buying an additional 44,458 shares in the last quarter. Kempner Capital Management Inc. acquired a new stake in shares of Pfizer during the first quarter worth approximately $2,439,000. Finally, Leo Wealth LLC acquired a new stake in shares of Pfizer during the fourth quarter worth approximately $2,171,000. Institutional investors and hedge funds own 68.36% of the company’s stock.
Pfizer Price Performance
Pfizer stock traded up $0.21 during midday trading on Thursday, hitting $28.60. The company’s stock had a trading volume of 7,089,055 shares, compared to its average volume of 38,254,461. The stock’s 50-day moving average price is $29.03 and its 200-day moving average price is $28.04. The company has a market capitalization of $162.06 billion, a PE ratio of -472.92, a price-to-earnings-growth ratio of 1.02 and a beta of 0.68. Pfizer Inc. has a 12 month low of $25.20 and a 12 month high of $35.28. The company has a quick ratio of 0.60, a current ratio of 0.86 and a debt-to-equity ratio of 0.65.
Pfizer Dividend Announcement
The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 3rd. Shareholders of record on Friday, July 26th were paid a dividend of $0.42 per share. The ex-dividend date was Friday, July 26th. This represents a $1.68 annualized dividend and a yield of 5.87%. Pfizer’s dividend payout ratio (DPR) is presently -2,799.53%.
Wall Street Analyst Weigh In
A number of analysts have recently weighed in on PFE shares. Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 price target on shares of Pfizer in a research report on Monday, August 19th. Daiwa America raised shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. Barclays raised their target price on Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 31st. StockNews.com upgraded Pfizer from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Finally, Wells Fargo & Company raised their target price on Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 31st. Eight analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $34.54.
View Our Latest Research Report on Pfizer
Pfizer Profile
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Recommended Stories
- Five stocks we like better than Pfizer
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- Recession or Not, These 3 Stocks Are Winners
- The How And Why of Investing in Oil Stocks
- Why NVIDIA Is More of a Screaming Buy Than Ever
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- Don’t Miss These 3 Stocks Set to Defy Expectations in September
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Free Report).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.